KIT FOR PREPARING INJECTABLE CARMUSTINE SOLUTIONS
The present invention relates to an improved kit for preparing injectable carmustine solutions, methods of preparing and administering such solutions, and methods of treatment with such solutions. The kit includes a product vial containing lyophilised carmustine and a diluent vial containing an ethanol-free non-aqueous diluent. Reconstitution of the lyophilised carmustine in the ethanol-free non-aqueous diluent results in a carmustine solution with improved solubility and stability.
1 - 19 . (canceled)
20 . A method of treating cancer in a patient in need thereof comprising
(a) (i) dissolving 300-600 mg of lyophilized carmustine in sterile propylene glycol to form a reconstituted solution having a carmustine concentration of about 33.3 mg/mL, and
(ii) storing the reconstituted solution at 2-8° C. for up to 480 hours prior to step (b), and after storage at 2-8° C. and prior to performing step (b), examining the reconstituted solution for crystal formation and if crystals are observed, re-dissolving by warming the reconstituted solution to room temperature with agitation,
(b) diluting the reconstituted solution with an aqueous 0.9% sodium chloride solution or an aqueous 5% dextrose solution to obtain an administrable solution, and
(c) administering by intravenous infusion the administrable solution of carmustine, wherein (i) at least 300 mg/m 2 of the carmustine is administered, and (ii) the carmustine is administered with at least one other chemotherapeutic agent.
21 . The method of claim 20 , wherein step (b) comprises administering at least 450 mg/m 2 of the carmustine.
22 . The method of claim 20 , wherein step (a)(i) comprises dissolving 300 mg of lyophilized carmustine in propylene glycol.
23 . The method of claim 20 , wherein step (a)(i) comprises dissolving 500 mg of lyophilized carmustine in propylene glycol.
24 . The method of claim 20 , wherein the carmustine is administered to the patient as part of a regimen with etoposide, cytarabine, and melphalan.
25 . The method of claim 20 , wherein the carmustine is administered to the patient as part of a regimen with cyclophosphamide and etoposide.
26 . The method of claim 20 , wherein the carmustine is administered to the patient as part of a regimen with etoposide, cytarabine, and cyclophosphamide.
27 . The method of claim 20 ,wherein the patient suffers from brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, metastatic brain tumors, multiple myeloma, relapsed or refractory Hodgkin's lymphoma, or relapsed or refractory Non-Hodgkin's lymphomas.
28 . A method for administering carmustine to a patient in need thereof comprising
(a) (i) dissolving 500 mg of lyophilized carmustine in sterile propylene glycol to form a reconstituted solution having a carmustine concentration of about 33.3 mg/mL, and
(ii) storing the reconstituted solution at 2-8° C. for up to 480 hours prior to step (b), and after storage at 2-8° C. and prior to performing step (b), examining the reconstituted solution for crystal formation and if crystals are observed, re-dissolving by warming the reconstituted solution to room temperature with agitation,
(b) diluting the reconstituted solution with an aqueous 0.9% sodium chloride solution or an aqueous 5% dextrose solution to obtain an administrable solution, and
(c) administering by intravenous infusion the administrable solution of carmustine, wherein (i) at least 300 mg/m 2 of the carmustine is administered, and (ii) the carmustine is administered with at least one other chemotherapeutic agent.
29 . The method of claim 28 , wherein step (b) comprises administering at least 450 mg/m 2 of the carmustine.
30 . The method of claim 28 , wherein the carmustine is administered to the patient as part of a regimen with etoposide, cytarabine, and melphalan.
31 . The method of claim 28 , wherein the carmustine is administered to the patient as part of a regimen with cyclophosphamide and etoposide.
32 . The method of claim 28 , wherein the carmustine is administered to the patient as part of a regimen with etoposide, cytarabine, and cyclophosphamide.